Pricing Log in Create free account
Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

70.09 1.38 +2.01%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Exelixis, Inc. (EXEL) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Exelixis, Inc. (EXEL) trades at a EV/EBITDA of 15.6×. Over the past ten years it has ranged from 0.0× (March 2017) to 145× (June 2017); the current reading is higher than 57% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 12.1× (10.88%)
FY2024 13.5× (59.95%)
FY2023 33.8× 89.88%
FY2022 17.8× 23.88%
FY2021 14.4× (65.79%)
FY2020 42.0× 252.24%
FY2019 11.9× 2.14%
FY2018 11.7× (77.96%)
FY2017 52.9× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 13.1× 2.35%
Jun 2026 12.8× 19.97%
Mar 2026 10.7× (11.29%)
Dec 2025 12.1× (1.12%)
43 more quarters

Against its own ten years

Low 0.0× High 145×
Ten-year median 14.2×
Current reading's percentile 57

EV/EBITDA against peers

Company EV/EBITDA
SMMT Summit Therapeutics PLC compare n/m
BNTX BioNTech SE Sponsored ADR compare n/m
BBIO BridgeBio Pharma, Inc. compare n/m
INSM Insmed, Inc. compare n/m
JAZZ Jazz Pharmaceuticals PLC compare 15.2×
EXEL Exelixis, Inc. 15.6×
ALNY Alnylam Pharmaceuticals, Inc. compare 17.8×
HALO Halozyme Therapeutics, Inc. compare 22.6×
ASND Ascendis Pharma A/S compare 49.5×
Biotechnology industry median 0.7×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on EXEL